Area of research
Hematology · Epidemiology
Research interest
Research interests include Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Multiple Myeloma Research and Treatments, and Cytomegalovirus and herpesvirus research.
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
A Day 14 Endpoint for Acute GVHD Clinical Trials
The Mount Sinai Acute Gvhd International Consortium (MAGIC) Model: An Integrated Clinical and Biomarker Grading System for Acute Graft-Versus-Host Disease (GVHD)
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
The utility of biomarkers in acute GVHD prognostication
Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
Round-Robin test for the histological diagnosis of acute colonic Graft-versus-Host disease validating established histological criteria and grading systems
Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study
A Day 14 Endpoint for Acute Gvhd Clinical Trials
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
Reduced splenic uptake on <sup>68</sup>Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
<sup>68</sup>Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
Comprehensive integrated NGS-based surveillance and contact-network modeling unravels transmission dynamics of vancomycin-resistant enterococci in a high-risk population within a tertiary care hospital